CAMK2G and hypertrophic cardiomyopathy: Acute ranolazine administration reduces both the intracellular Na+ and Ca2+ levels and CaMKII activity, thus contributing to the reduction of hypertrophic cardiomyopathy-related cardiac remodeling myocardial dysfunction [125].